Effects of benralizumab in patients with severe eosinophilic asthma (SEA): A plain language summary of the ANANKE study.

Canonica GW, Consani L, Malerba L, Pelaia G, Vultaggio A, ANANKE investigators

DOI: 10.1080/1750743x.2024.2386899
Published: 2024
Container: Immunotherapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/1750743x.2024.2386899,
  title = {Effects of benralizumab in patients with severe eosinophilic asthma (SEA): A plain language summary of the ANANKE study.},
  author = {Canonica GW and Consani L and Malerba L and Pelaia G and Vultaggio A and ANANKE investigators},
  year = {2024},
  journal = {Immunotherapy},
  doi = {10.1080/1750743x.2024.2386899},
  url = {https://doi.org/10.1080/1750743x.2024.2386899}
}

RIS

TY  - JOUR
TI  - Effects of benralizumab in patients with severe eosinophilic asthma (SEA): A plain language summary of the ANANKE study.
AU  - Canonica GW
AU  - Consani L
AU  - Malerba L
AU  - Pelaia G
AU  - Vultaggio A
AU  - ANANKE investigators
PY  - 2024
JO  - Immunotherapy
DO  - 10.1080/1750743x.2024.2386899
UR  - https://doi.org/10.1080/1750743x.2024.2386899
ER  -

APA

GW, C., L, C., L, M., G, P., A, V., & investigators, A. (2024). Effects of benralizumab in patients with severe eosinophilic asthma (SEA): A plain language summary of the ANANKE study.. Immunotherapy. https://doi.org/10.1080/1750743x.2024.2386899

Source records

pubmed · retrieved 2026-09-26T06:09:15.410Z